| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. (AXSM) has 9 insiders with recent SEC Form 4 filings, including 12 buys and 0 sells. AXSM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 58.4K | $14.11M | -572 | |
| Dir | 30.4K | $7.34M | -12,180 | |
| CEO | 24.1K | $5.82M | - | |
| Other | 23.7K | $5.73M | - | |
| Dir | 11.4K | $2.76M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2019 | Pizzie Nick50 | Chief Financial Officer | Buy | 2,180 | $24.80 | $54,064.00 | +5.7% | |
| Jun 26, 2019 | Coleman Mark | Director | Buy | 16,200 | $23.10 | $374,280.00 | +1.2% | |
| Jun 11, 2019 | Pizzie Nick50 | Chief Financial Officer | Buy | 1,920 | $20.80 | $39,936.00 | New | |
| May 23, 2019 | Saad Mark E50 | Director | Buy | 3,500 | $22.33 | $78,155.00 | +99.9% | |
| May 13, 2019 | Coleman Mark | Director | Buy | 4,650 | $21.44 | $99,696.00 | +0.7% | |
| Mar 19, 2019 | Pizzie Nick50 | Chief Financial Officer | Buy | 5,400 | $12.58 | $67,938.60 | +17.4% | |
| Mar 19, 2019 | Coleman Mark | Director | Buy | 5,100 | $12.18 | $62,118.00 | New | |
| Jun 19, 2018 | Pizzie Nick50 | Chief Financial Officer | Buy | 31,000 | $3.10 | $96,080.00 | +7,750% | |
| Dec 23, 2015 | Kaye Randall | Chief Medical Officer | Buy | 1,000 | $9.03 | $9,026.00 | +19.9% |